Special Episode, Part 2: Coronavirus - Building Models to Rebuild Economies
When do we return to work? The market reaction? The drug pipeline? Chief Cross-Asset Strategist Andrew Sheets and Head Biotech Equity Analyst Matthew Harrison continue their discussion on the impact of the Covid-19 pandemic.
14 Huhti 202010min
Mike Wilson: U.S. Markets React to Fed Moves
If there is one lesson to be learned from the financial repression era it's that when risk premium appears, investors may want to make moves before it evaporates.
13 Huhti 20204min
Special Episode: Coronavirus – Building Models to Rebuild Economies
How do you track a virus, a global economy and a road to recovery? On this special episode, an engaging conversation with our Chief Cross-Asset Strategist and Head Biotech Equity Analyst.
9 Huhti 20209min
Michael Zezas: Another Dose of Fiscal Stimulus?
The U.S. Congress has been debating ways to flatten another worrying curve: the sliding economic growth curve. What form could additional fiscal stimulus take?
8 Huhti 20202min
Mike Wilson: What Are Markets Thinking?
Asset prices often reflect the obvious before it becomes obvious. So the question for investors now is, "What is the market thinking about that's not obvious?"
6 Huhti 20203min
Andrew Sheets: Optimism for Credit Markets
Even as economic and public health data get worse, recent changes in three key factors make global credit markets an attractive option. Our Chief Cross-Asset Strategist, Andrew Sheets, explains.
3 Huhti 20202min
Michael Zezas: What Does the CARES Act Buy?
The $2 trillion CARES Act includes a variety of provisions that will help preserve the financial health of state and local governments, hospitals and airports. Here’s what’s inside.
1 Huhti 20202min
Mike Wilson: U.S. Equities - Is the Worst Behind Us?
Although economic and earnings data could be gloomy over the next month, have equity markets already discounted the bad news? Detailed analysis from Chief Investment Officer Mike Wilson.
30 Maalis 20203min
